Limbitis secondary to autologous serum eye drops in a patient with atopic keratoconjunctivitis

Jeffrey David Welder, Pejman Bakhtiari, Ali R Djalilian, Jeffrey David Welder, Pejman Bakhtiari, Ali R Djalilian

Abstract

Purpose. Report a case of limbitis secondary to autologous serum eye drops in a patient with atopic keratoconjunctivitis. Design. Interventional case report. Methods. A 32-year-old African American female with atopic keratoconjunctivitis (AKC) presented with chronic dry eye and diffuse punctate epithelial erosions refractory to conservative treatment. She was initially managed with cyclosporine ophthalmic 0.05% in addition to preservative-free artificial tears and olopatadine hydrochloride 0.2% for 6 months. She was later placed on autologous serum eye drops (ASEDs) and 4 weeks into treatment developed unilateral limbitis. The limbitis resolved shortly after stopping ASEDs in that eye; however, the drops were continued in the contralateral eye, which subsequently developed limbitis within 2 weeks. ASEDs were discontinued in both eyes, and the patient has remained quiet ever since. Results. Patient with a history of AKC and no prior history of limbitis developed limbitis shortly after starting ASEDs, which resolved promptly after discontinuation of therapy with no subsequent recurrence of inflammation. Conclusion. ASEDs are widely used in the treatment of complicated or treatment refractory dry eye. The potential side effects should be kept in mind when prescribing ASEDs for any patient, especially in those with underlying immunological diseases and circulating inflammatory factors.

Figures

Figure 1
Figure 1
External photographs of the patient reported in our case. Marked temporal limbal injection and focal conjunctival elevation is apparent.

References

    1. Noble BA, Loh RSK, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. British Journal of Ophthalmology. 2004;88(5):647–652.
    1. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106(10):1984–1989.
    1. Geerling G, MacLennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. British Journal of Ophthalmology. 2004;88(11):1467–1474.
    1. López-García JS, García-Lozano I, Rivas L, Martínez-Garchitorena J. Use of autologous serum in ophthalmic practice. Archivos de la Sociedad Espanola de Oftalmologia. 2007;82(1):9–20.
    1. Ohashi Y, Motokura M, Kinoshita Y, et al. Presence of epidermal growth factor in human tears. Investigative Ophthalmology and Visual Science. 1989;30(8):1879–1882.
    1. Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder SC. Transforming growth factor beta-1 and beta-2 in human tear fluid. Current Eye Research. 1996;15(6):605–614.
    1. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjogren’s syndrome. British Journal of Ophthalmology. 1999;83(4):390–395.
    1. Matsumoto Y, Dogru M, Goto E, et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111(6):1115–1120.
    1. Ogawa Y, Okamoto S, Yamada M, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplantation. 2003;31(7):579–583.
    1. Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea. 2001;20(8):807–810.
    1. Noda-Tsuruya T, Asano-Kato N, Toda I, Tsubota K. Autologous serum eye drops for dry eye after LASIK. Journal of Refractive Surgery. 2006;22(1):61–66.
    1. Leite SC, de Castro RS, Alves M, et al. Risk factors and characteristics of ocular complications, and efficacy of autologous serum tears after haematopoietic progenitor cell transplantation. Bone Marrow Transplantation. 2006;38(3):223–227.
    1. McDonnell PJ, Schanzlin DJ, Rao NA. Immunoglobulin deposition in the cornea after application of autologous serum. Archives of Ophthalmology. 1988;106(10):1423–1425.
    1. Poon AC, Geerling G, Dart JKG, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. British Journal of Ophthalmology. 2001;85(10):1188–1197.
    1. Stumpf T, Luqmani N, Sumich P, Cook S, Tole D. Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis. Cornea. 2006;25(10):1147–1149.
    1. Bielory L. Ocular allergy guidelines: a practical treatment algorithm. Drugs. 2002;62(11):1611–1634.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere